Arthneeti

Viyash Scientific Q1 FY27 Share Price & Earnings Call Analysis

₹224.55-1.08% today
Market cap
₹9,920 Cr
P/E
44.79
ROE
7.39%
PEG
0.61
Price to sales
2.78
Debt to equity
0.17
52W high / low
₹298 / ₹178
Sales growth (5Y)
20.23%
EBITDA margin
19.90%
Net profit margin
7.31%
Promoter holding
49.24%
Sales (last year)
₹3,575 Cr

Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.

Guidance scorecard · Q1 FY27 call

What Viyash Scientific Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#68of 83 in
Pharmaceuticals & Biotechnology
Revenue10–20%MarginsFlatCapexPlannedFundraisingPlannedOrder bookWhat management said

RevenueQ1 FY27 call

10–20%
  • Expect steady double-digit revenue growth with 15%-17% growth in next 2 years (up to 2028) before acceleration.
  • Significant growth anticipated post-2029, driven by patent expiries on Animal Health (2027-2033) and Human API products (post-2030).
  • Majority of new product revenues expected from 2029 onwards, considering 3-5 years gestation for product development and regulatory approvals.
  • Animal Health segment growing faster, currently about one-third of API revenue, with focus on formulations and expanding manufacturing capacity.
  • European acquisition (BioForLife) to contribute substantially after 2-3 years (post-2028) with estimated €150-200 million revenue by 2032.
  • Emerging markets (Turkey, Brazil, Mexico) showing strong volume growth (~25%), expected to sustain momentum.

2 more points from Viyash Scientific Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Viyash Scientific Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Capex guidance for FY’27 is around Rs. 250 crores to Rs. 300 crores.
  • Current capital allocation is balanced; majority business (90%) is mature and requires limited new investment.
  • New investments focus on R&D, manufacturing expansion, and strategic areas like high potent API and formulation capabilities.
  • Manufacturing plant for companion animal products being prepared with expected readiness by January-February following equipment orders placed and design finalization.
  • Company plans selective inorganic growth via acquisitions aligned with strategic direction (Animal Health, CDMO, complex molecules).
  • Interest cost restructuring underway to optimize financing costs.

2 more points from Viyash Scientific Ltd's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

Planned

See what Viyash Scientific Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

  • Post-acquisition of BioForLife (Italy), registrations and marketing are expected to take 18-24 months before significant revenue impact.
  • Product launches and R&D investments for companion animals are ramping up, with manufacturing readiness expected by January 2027.
  • A strong product pipeline in emerging markets (Turkey, Brazil, Mexico) and Europe supports growth.
  • API business faced some quarter-on-quarter timing delays due to raw material volatility but expects a strong quarter with many orders returning.

2 more points from Viyash Scientific Ltd's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Viyash Scientific Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Viyash Scientific Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Viyash Scientific Ltd announcements

All announcements →

Financials of Viyash Scientific Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Viyash Scientific Ltd

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +367333346329361390369774402441850858920
Expenses +370341331307329348330674355389677683736
Operating Profit-3-815223242391004652173176184
OPM %-1%-2%4%7%9%11%11%13%12%12%20%20%20%
Other Income +-60-23107-1304136-2716
Interest11101313121614211514181715
Depreciation15141515161617581615595960
Profit before tax-89-56-31312824162610273125
Tax %4%-38%123%-617%52%24%20%-71%36%31%29%34%47%
Net Profit +-92-35-711196421018734966
EPS in Rs-3.75-1.40-0.340.33-0.040.260.101.780.370.572.180.881.19

Financials of Viyash Scientific Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +4436066848481,0391,1791,3621,4131,4211,3701,5513,420
Expenses +4255506417659141,0091,1501,3031,4091,3081,3902,768
Operating Profit185643831251702121091261162653
OPM %4%9%6%10%12%14%16%8%1%4%10%19%
Other Income +48149436910-011-58-610-1
Interest433828333336241636486169
Depreciation3246404142515152566266234
Profit before tax-8-14-17444599413753-138-5544349
Tax %40%19%-3%3%3%13%24%15%-11%-46%27%36%
Net Profit +-12-16-16431578210445-122-3032225
EPS in Rs-0.70-0.78-0.5717.301.972.813.841.65-4.86-1.440.874.06
Dividend Payout %0%0%0%1%10%0%13%0%0%0%0%0%

Financials of Viyash Scientific Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital304849494950505050505087
Reserves618989285996576376786426496076542,824
Borrowings +473312416305325343277365444488481490
Other Liabilities +3432655033803464243813783743894121,228
Total Liabilities9081,5231,8961,3321,3781,4541,3861,4351,5171,5341,5984,628
Fixed Assets +4745866844764985775365646055925862,105
CWIP392433182313311255161669
Investments5942842823918017183380400
Other Assets +3364857515996776937378218569229962,455
Total Assets9081,5231,8961,3321,3781,4541,3861,4351,5171,5341,5984,628

Financials of Viyash Scientific Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-24-0-74511611511531173183323
Cash from Investing Activity +-157-310-1167-68-7210-94-65-6-25-84
Cash from Financing Activity +179309147-57-20-43-1396732-1-61-123
Net Cash Flow-1-224-5280-144-1623-2115
Free Cash Flow-137-63-820927570-1-581954225
CFO/OP-143%-3%5%65%92%75%75%52%263%73%69%59%

Financials of Viyash Scientific Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days9511613611198999385888985112
Inventory Days153164165125134132139160152166173188
Days Payable147175208127141133119119107121115140
Cash Conversion Cycle101105931109298112126132135143160
Working Capital Days-11165-252033295154463070111
ROCE %8%2%1%40%9%12%16%6%-3%0%8%19%

Guidance history

How Viyash Scientific Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%FlatPlannedPlanned—
Q4 FY26 call →10–20%FlatPlanned——
Q4 FY26 call →10–20%FlatPlanned——
Q3 FY26 call →10–20%FlatPlannedPlanned—

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

29out of 100

Momentum score · price trend

29 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+5.0%65%
Last 6 months+8.5%65%
Last 3 months−15.9%27%

The price is 25.5% below its all-time high of ₹303.4 (16 Jul 2021). Stocks more than 20% below their peak have their score halved, so 57 became 29.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Viyash Scientific Ltd: 0.4 × 65 + 0.4 × 65 + 0.2 × 27 = 57, halved to 29 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 16 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Viyash Scientific Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd